CLAIMS

1. A composition comprising a particulate material, and further comprising at least two pharmaceutical drug agents, and wherein the drug agents are anti-cancer drugs and/or drugs used in treatment of cancer, wherein the particulate material is hydroxyapatite in any crystalline form or configuration wherein the particles in the particulate material comprises or consist of particles in size range of about 1 µm to about 20 µm or in range of about 20 nm to about 120 nm,
and wherein one pharmaceutical drug agent is one or more bisphosphonates and one or more anthracyclines selected from zoledronic acid and anthracyclins is doxorubicin respectively, or any suitable pharmaceutically acceptable salts or ester thereof.

2. The composition according to claim 1, wherein at least one of the pharmaceutical drugs are capable of binding to the particulate material.

3. The composition according to any of the preceding claims, wherein the particles in the particulate material is a combination of different particles sizes in the micrometre range and in the nanometre range.

4. The composition according to any one of preceding claims, wherein the anthracycline is doxorubicin, and the bisphosphonate is zoledronic acid or any pharmaceutically acceptable salt or ester thereof, and the hydroxyapatite is present in particle size range of about 20 nm to about 80 nm, or about 50 nm.

5. A composition according to any one of the preceding claims for use in the treatment of cancer selected from bone related cancer, such as e.g.or osteosarcoma, wherein the composition is administered once every 7 days.

6. A method of treating a subject suffering from a bone related cancer, the method comprising administering to the subject in need thereof a composition comprising;
(i) hydroxyapatite as a particulate material, in a particle size of of about 1 µm to about 20 µm or in range of about 20 nm to about 120 nm, ,
(ii) doxorubicin,
(iii) zoledronic acid or any suitable pharmaceutically acceptable salts thereof, wherein the composition is administered once every 7 days.

7.6. The methodcomposition for use according to claim 65, wherein
(a) the doxorubicin is mixed with the particulate material prior to being administered to the subject or,
(b) the zoledronic acid, or any suitable pharmaceutically acceptable salts thereof, is mixed with the particulate material prior to being administered to the subject or,
(c) the doxorubicin, and the zoledronic acid, or any suitable pharmaceutically acceptable salts thereof, is mixed with the particulate material prior to being administered to the subject.